Tide Pharmaceutical

Beijing Tide Pharmaceutical Co., Ltd. (hereinafter referred to as Tide Pharmaceutical) is a Sino-foreign joint venture established in 1995, located at the core of Beijing Economic-Technological Development Area. It is the first high-tech pharmaceutical enterprise in China capable of R&D, production, and sales of a series of targeted drugs.
Through continuous innovation and development, Tide Pharmaceutical has been successively recognized by the Ministry of Science and Technology and the Beijing Municipal Government as "National Key High-Tech Enterprise", "Beijing Advanced Technology Enterprise with Foreign Investment", and "Beijing High-Tech Enterprise". It has been selected as an innovative pilot enterprise in Zhongguancun National Innovation Demonstration Zone and a "Ten-Hundred-Thousand Project" enterprise, and has been rated by Forbes magazine as one of China's top 100 potential enterprises. In 2012, Tide Pharmaceutical successively won honors such as "Outstanding Contribution Enterprise for Beijing Biomedical Industry Leapfrog Development Project (G20 Project)", "Pioneer Enterprise for Preparation Internationalization of Chinese Pharmaceutical Enterprises", and "Investment Value Enterprise in China's Pharmaceutical Industry". Since 2008, the company has consistently ranked among the top ten taxpayers in the Beijing Economic-Technological Development Area, where giants like Mercedes-Benz, Bayer, and Nokia gather, and rose to fourth place in 2012. According to the 2012 statistics of the Ministry of Industry and Information Technology, the company's main business revenue ranked among the top 100 pharmaceutical industry enterprises nationwide.
In 2008, Tide Pharmaceutical's injection production line took the lead in China to obtain the "Certificate of Foreign Manufacturer of Pharmaceuticals" issued by the Ministry of Health, Labour and Welfare of Japan, truly achieving the export of domestic injections to overseas markets and playing an important exemplary role in the industry. Tide Pharmaceutical is dedicated to becoming the leading targeted pharmaceutical enterprise. Over the past decade plus, the company has focused on the R&D, production, and market promotion of targeted drugs, with a professional sales team covering the prescription drug market of more than 2,000 large and medium-sized hospitals across 29 provinces, autonomous regions, and municipalities.
Adhering to the concept of technological innovation, Tide Pharmaceutical has, after more than ten years of development, established four high-end technology platforms: lipid microspheres, liposomes, biological preparations, and transdermal patches, possessing multiple core technologies with independent intellectual property rights. Tide Pharmaceutical has built an advanced new drug R&D system. The upcoming new R&D center, covering approximately 32,000 square meters, is custom-designed by a professional American design firm, equipped with formulation trial production and analytical research equipment, and provides international-level laboratory, pilot-scale, and research environments. The company's targeted drug brand portfolio and new product pipeline will continue to maintain its leading position and differentiated competitiveness in the targeted drug market, solidifying its leadership in the targeted drug field.
Tide Pharmaceutical adheres to a people-oriented approach, fostering a high-performance organizational culture, advocating the construction of a learning organization, encouraging employees to continuously learn, actively strive, seek truth and pragmatism, and fully leverage their strengths and creativity. Tide provides every employee with excellent professional training opportunities, broad development space, and a harmonious and upward organizational atmosphere. Relying on good cooperative relationships with foreign research institutions and enterprises, the company regularly selects employees for overseas training to learn advanced research techniques and management methods.
Upholding the tenet of "Caring for Life, Pursuing Excellence and Innovation", Tide Pharmaceutical aims to develop innovative drugs with independent intellectual property rights. With independent innovation, self-developed R&D, and introduction-absorption-reinnovation as the development directions, the company is rooted in China and looks to the world, striving to provide society with better new drug products and improve public health!
Company Address: No. 8 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing